Inogen Inc
$ 6.30
-4.40%
11 Jun - close price
- Market Cap 171,923,000 USD
- Current Price $ 6.30
- High / Low $ 6.65 / 6.27
- Stock P/E N/A
- Book Value 6.68
- EPS -0.91
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.13 %
- 52 Week High 9.13
- 52 Week Low 5.34
About
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Analyst Target Price
$12.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-24 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.14 | -0.15 | -0.02 | -0.02 | -0.11 | -0.24 | -0.11 | -0.07 | -0.45 | -1.14 | -0.36 | -0.4 |
| Estimated EPS | -0.21 | -0.3424 | -0.09 | -0.09 | -0.25 | -0.49 | -0.27 | -0.39 | -0.58 | -0.62 | -0.23 | -0.6 |
| Surprise | 0.07 | 0.1924 | 0.07 | 0.07 | 0.14 | 0.25 | 0.16 | 0.32 | 0.13 | -0.52 | -0.13 | 0.2 |
| Surprise Percentage | 33.3333% | 56.1916% | 77.7778% | 77.7778% | 56% | 51.0204% | 59.2593% | 82.0513% | 22.4138% | -83.871% | -56.5217% | 33.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INGN
2026-06-11 20:39:29
Inogen Inc. stockholders approved an expanded 2023 Equity Incentive Plan, adding 750,000 shares for awards, and re-elected two Class III directors. While executive compensation and auditor ratification also passed, a proposal to declassify the board did not receive approval, maintaining the company's staggered board structure. Approximately 76.28% of eligible shares were represented at the annual meeting.
2026-06-10 05:09:25
Inogen Inc. director Elizabeth Mora was granted 28,081 restricted stock units (RSUs) at no cost, increasing her direct holdings to 107,261 shares. These RSUs will vest in approximately one year, contingent on her continued service. This transaction is considered a neutral event, aligning the director's incentives with shareholder interests without immediate dilution.
2026-06-10 04:39:57
Inogen director Jamali Vafa was granted 28,081 shares of common stock as a restricted stock unit (RSU) award on June 5, 2026, at no cash cost. Following this award, Vafa directly holds 43,081 shares. The RSUs are set to vest on the earlier of one year after the grant date or the day before the next annual stockholder meeting, contingent upon his continued service.
2026-06-09 20:39:57
Inogen Inc. director Heather D. Rider was granted 28,081 restricted stock units (RSUs) as an equity award, bringing her direct holdings to 116,282 shares. These RSUs will vest on the earlier of one year from the grant date or the day before the next Annual Meeting of stockholders, contingent upon her continued service. This transaction aligns her incentives with shareholder interests by linking her compensation to the company's equity performance.
2026-06-09 20:39:57
Inogen Inc. director Glenn S. Boehnlein was granted 28,081 shares of Common Stock as a restricted stock unit award on June 5, 2026. The award, valued at $0.00 per share, will vest on the earlier of one year from the grant date or the day before the next Annual Meeting of stockholders, contingent on his continued service. Following this transaction, Boehnlein directly holds 104,966 shares of Inogen common stock.
2026-06-07 17:09:34
The article provides an analyst forecast for INGN, indicating no current consensus ratings (buy, hold, or sell) and no 12-month average price target. It outlines various financial metrics and types of analyst estimates that would typically be included, such as revenue, EBITDA, EPS, and net income, but shows them as unpopulated for INGN. The piece appears to be a template or a snapshot of an undeveloped analyst report for the company.
